NIDDM
MCID: DBT026
MIFTS: 80

Diabetes Mellitus, Noninsulin-Dependent (NIDDM) malady

Categories: Genetic diseases, Endocrine diseases, Metabolic diseases

Aliases & Classifications for Diabetes Mellitus, Noninsulin-Dependent

Aliases & Descriptions for Diabetes Mellitus, Noninsulin-Dependent:

Name: Diabetes Mellitus, Noninsulin-Dependent 54 24 13 38
Insulin Resistance 54 29 52 69
Diabetes Mellitus, Non-Insulin-Dependent 54 66 69
Type 2 Diabetes Mellitus 38 12 14
Niddm 12 66 52
Diabetes Mellitus, Type 2 54 42
Diabetes Mellitus Type Ii 66 29
Diabetes Mellitus, Noninsulin-Dependent, Association with 54
Diabetes Mellitus, Noninsulin-Dependent, Late Onset 54
Diabetes Mellitus, Type 2, Susceptiblity to 54
Diabetes Mellitus, Noninsulin-Dependent, 2 54
Hypertension, Insulin Resistance-Related 54
Non-Insulin-Dependent Diabetes Mellitus 12
Noninsulin-Dependent Diabetes Mellitus 66
Adult-Onset Diabetes Mellitus 66
Diabetes Mellitus, Type Ii 54
Type Ii Diabetes Mellitus 12
Diabetes Mellitus Type 2 66
Maturity-Onset Diabetes 66
Diabetes Mellitus 69
Diabetes, Type 2 54
Type Ii Diabetes 14
Diabetes Type 2 41
T2d 66

Characteristics:

HPO:

32
diabetes mellitus, noninsulin-dependent:
Inheritance autosomal dominant inheritance
Onset and clinical course late onset


Classifications:



Summaries for Diabetes Mellitus, Noninsulin-Dependent

MedlinePlus : 41 diabetes means your blood glucose, or blood sugar, levels are too high. with type 2 diabetes, the more common type, your body does not make or use insulin well. insulin is a hormone that helps glucose get into your cells to give them energy. without insulin, too much glucose stays in your blood. over time, high blood glucose can lead to serious problems with your heart, eyes, kidneys, nerves, and gums and teeth. you have a higher risk of type 2 diabetes if you are older, obese, have a family history of diabetes, or do not exercise. having prediabetes also increases your risk. prediabetes means that your blood sugar is higher than normal but not high enough to be called diabetes. the symptoms of type 2 diabetes appear slowly. some people do not notice symptoms at all. the symptoms can include being very thirsty urinating often feeling very hungry or tired losing weight without trying having sores that heal slowly having blurry eyesight blood tests can show if you have diabetes. one type of test, the a1c, can also check on how you are managing your diabetes. many people can manage their diabetes through healthy eating, physical activity, and blood glucose testing. some people also need to take diabetes medicines. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Diabetes Mellitus, Noninsulin-Dependent, also known as insulin resistance, is related to diabetes mellitus, noninsulin-dependent 1 and insulin-resistant acanthosis nigricans, type a, and has symptoms including type ii diabetes mellitus, insulin resistance and angina pectoris. An important gene associated with Diabetes Mellitus, Noninsulin-Dependent is NEUROD1 (Neuronal Differentiation 1), and among its related pathways/superpathways are Type II diabetes mellitus and Developmental Biology. The drugs Linagliptin and Metformin have been mentioned in the context of this disorder. Affiliated tissues include Pancreas and Adipose, and related phenotypes are Decreased viability and endocrine/exocrine gland

Disease Ontology : 12 A diabetes mellitus that involves high blood glucose resulting from cells fail to use insulin properly.

UniProtKB/Swiss-Prot : 66 Diabetes mellitus, non-insulin-dependent: A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body's own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.

Description from OMIM: 125853

Related Diseases for Diabetes Mellitus, Noninsulin-Dependent

Diseases in the Diabetes Mellitus, Noninsulin-Dependent family:

Diabetes Mellitus, Noninsulin-Dependent 1 Diabetes Mellitus, Noninsulin-Dependent, 2
Diabetes Mellitus, Noninsulin-Dependent, 5 Kcnj11-Related Susceptibility to Noninsulin-Dependent Diabetes Mellitus

Diseases related to Diabetes Mellitus, Noninsulin-Dependent via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 73)
id Related Disease Score Top Affiliating Genes
1 diabetes mellitus, noninsulin-dependent 1 12.4
2 insulin-resistant acanthosis nigricans, type a 12.4
3 diabetes mellitus, noninsulin-dependent, 2 12.3
4 diabetes mellitus, noninsulin-dependent, with acanthosis nigricans and hypertension 12.3
5 diabetes mellitus, noninsulin-dependent, 5 12.3
6 diabetes mellitus, insulin-resistant, with acanthosis nigricans 12.3
7 kcnj11-related susceptibility to noninsulin-dependent diabetes mellitus 12.3
8 insulin-resistance type b 12.0
9 rabson-mendenhall syndrome 12.0
10 hair-an syndrome 11.9
11 severe early-onset obesity-insulin resistance syndrome due to sh2b1 deficiency 11.9
12 microcephalic primordial dwarfism-insulin resistance syndrome 11.9
13 short fifth metacarpals-insulin resistance syndrome 11.9
14 short syndrome 11.7
15 lipodystrophy, familial partial, type 3 11.5
16 leprechaunism 11.4
17 hypertriglyceridemia 11.3
18 maturity-onset diabetes of the young 11.3
19 prader-willi syndrome 11.2
20 werner syndrome 11.2
21 spinal and bulbar muscular atrophy of kennedy 11.2
22 diabetes and deafness, maternally inherited 11.2
23 mody, type ii 11.1
24 diabetes mellitus, permanent neonatal 11.0
25 diabetes mellitus, transient neonatal, 1 11.0
26 autoimmune polyendocrine syndrome, type ii 11.0
27 alstrom syndrome 10.9
28 laron dwarfism 10.9
29 maturity-onset diabetes of the young 6 10.8 ABCC8 AKT2 ENPP1 GCGR GCK GPD2
30 diabetes mellitus, transient neonatal, 3 10.7
31 pancreatic cancer 10.7
32 diabetes mellitus, insulin-dependent, 20 10.6 GCK HNF1B HNF4A INSR IRS1 NEUROD1
33 peroneal neuropathy 10.6 ABCC8 GCK IRS1 PPARG RETN SLC30A8
34 congenital stationary night blindness 10.6 ABCC8 GCK HNF1B HNF4A IRS1 NEUROD1
35 body dysmorphic disorder 10.6 ABCC8 GCK IRS1 PPARG RETN TCF7L2
36 brain stem glioma 10.6 ABCC8 GCGR GCK INSR IRS1 PPARG
37 antidepressant type abuse 10.6 GCK INSR IRS1 RETN TCF7L2
38 blind loop syndrome 10.6 GCK INSR IRS1 PPARG RETN
39 von hippel-lindau syndrome 10.6 ABCC8 ENPP1 INSR IRS1 LIPC PPARG
40 mosaic trisomy 13 10.5 ABCC8 GCK HNF1B HNF4A
41 diabetic cataract 10.5 ABCC8 GCK HNF4A INSR
42 distal muscular dystrophy 10.5 ABCC8 GCK HNF1B NEUROD1
43 exostosis 10.5 ABCC8 GCK HNF4A INSR
44 maturity-onset diabetes of the young, type 13 10.5 ABCC8 GCK HNF4A
45 hyperlipoproteinemia type iv 10.5 PPARG SLC30A8 TCF7L2
46 neurogenic arthropathy 10.5 ABCC8 GCK IRS1
47 diaphanospondylodysostosis 10.4 ABCC8 GCK
48 hypercholesterolemia, familial 10.4 ABCC8 INSR
49 nosophobia 10.4 ABCC8 GCK
50 adrenal adenoma 10.4 IRS1 PPARG RETN

Graphical network of the top 20 diseases related to Diabetes Mellitus, Noninsulin-Dependent:



Diseases related to Diabetes Mellitus, Noninsulin-Dependent

Symptoms & Phenotypes for Diabetes Mellitus, Noninsulin-Dependent

Symptoms by clinical synopsis from OMIM:

125853

Clinical features from OMIM:

125853

Human phenotypes related to Diabetes Mellitus, Noninsulin-Dependent:

32
id Description HPO Frequency HPO Source Accession
1 type ii diabetes mellitus 32 HP:0005978
2 insulin resistance 32 HP:0000855

UMLS symptoms related to Diabetes Mellitus, Noninsulin-Dependent:


angina pectoris, tremor, equilibration disorder, symptoms

GenomeRNAi Phenotypes related to Diabetes Mellitus, Noninsulin-Dependent according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.3 MAPK8IP1
2 Decreased viability GR00221-A-1 10.3 INSR GCK IRS1 PPARG AKT2
3 Decreased viability GR00221-A-2 10.3 INSR GCK IRS1 PPARG
4 Decreased viability GR00221-A-3 10.3 INSR GCK PPARG AKT2
5 Decreased viability GR00221-A-4 10.3 INSR GCK PPARG MAPK8IP1 AKT2
6 Decreased viability GR00231-A 10.3 GCK
7 Decreased viability GR00301-A 10.3 AKT2 MAPK8IP1
8 Decreased viability GR00342-S-2 10.3 IRS1
9 Decreased viability GR00342-S-3 10.3 IRS1 MAPK8IP1 AKT2
10 Decreased viability in esophageal squamous lineage GR00235-A 9.32 ABCC8 GCGR HMGA1 HNF1B HNF4A INSR

MGI Mouse Phenotypes related to Diabetes Mellitus, Noninsulin-Dependent:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.24 ABCC8 AKT2 GCGR GCK GPD2 HNF1B
2 homeostasis/metabolism MP:0005376 10.21 GCGR GCK GPD2 HNF1B HNF4A INSR
3 growth/size/body region MP:0005378 10.2 AKT2 ENPP1 GCGR GCK GPD2 HNF1B
4 adipose tissue MP:0005375 10.06 AKT2 ENPP1 GCGR GPD2 INSR IRS1
5 liver/biliary system MP:0005370 10 GPD2 HNF1B HNF4A INSR IRS1 MAPK8IP1
6 mortality/aging MP:0010768 9.8 AKT2 ENPP1 GCGR GCK GPD2 HNF1B
7 muscle MP:0005369 9.17 IRS1 PPARG TCF7L2 AKT2 ENPP1 HNF1B

Drugs & Therapeutics for Diabetes Mellitus, Noninsulin-Dependent

Drugs for Diabetes Mellitus, Noninsulin-Dependent (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1079)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Linagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1 668270-12-0 10096344
2
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
3
Voglibose Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83480-29-9 444020
4
Repaglinide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 135062-02-1 65981
5
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1 160337-95-1
6
Saxagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1 361442-04-8 11243969
7
Zinc Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 7440-66-6 32051 23994
8
Liraglutide Approved Phase 4,Phase 3,Phase 2,Phase 1 204656-20-2
9
Orlistat Approved, Investigational Phase 4,Phase 2,Phase 1 96829-58-2 3034010
10
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 111025-46-8 4829
11
Gliclazide Approved Phase 4,Phase 3,Phase 2,Phase 1 21187-98-4 3475
12
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 141758-74-9 15991534
13
Glipizide Approved Phase 4,Phase 3,Phase 2,Phase 1 29094-61-9 3478
14
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
15
Acarbose Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 56180-94-0 441184
16
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Phase 1 133107-64-9
17
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1 116094-23-6 16132418
18
Insulin Detemir Approved Phase 4,Phase 3,Phase 1 169148-63-4 5311023
19
Glimepiride Approved Phase 4,Phase 3,Phase 2,Phase 1 93479-97-1 3476
20
Atenolol Approved Phase 4 29122-68-7 2249
21
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2 128-13-2 31401
22
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
23
Glyburide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10238-21-8 3488
24
Vildagliptin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 274901-16-5 6918537
25
Alogliptin Approved Phase 4,Phase 3,Phase 2,Phase 1 850649-61-5 11450633
26
Fluvastatin Approved Phase 4 93957-54-1 1548972
27
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137862-53-4 60846
28
Insulin-glulisine Approved Phase 4,Phase 3,Phase 2,Phase 1 207748-29-6
29
Ramipril Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 87333-19-5 5362129
30
Ticlopidine Approved Phase 4,Phase 2 55142-85-3 5472
31
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2 75847-73-3 5362032 40466924
32
Enalaprilat Approved Phase 4,Phase 3,Phase 2 76420-72-9 6917719
33
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1 88150-42-9 2162
34
Clonidine Approved Phase 4,Phase 3 4205-90-7 2803
35
Doxazosin Approved Phase 4 74191-85-8 3157
36
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 1 54-31-9 3440
37
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-93-5 3639
38
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 138402-11-6 3749
39
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
40
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
41
Nitric Oxide Approved Phase 4,Phase 2,Phase 1 10102-43-9 145068
42
Cilostazol Approved Phase 4,Phase 3 73963-72-1 2754
43
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
44
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-18-4 6010
45
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
46
Pentoxifylline Approved, Investigational Phase 4,Phase 2 6493-05-6 4740
47
Acetaminophen Approved Phase 4,Phase 3,Phase 1,Early Phase 1 103-90-2 1983
48
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
49
Lisinopril Approved, Investigational Phase 4,Phase 3,Phase 1 83915-83-7 5362119
50
Oxymetazoline Approved Phase 4,Phase 1 1491-59-4 4636

Interventional clinical trials:

(show top 50) (show all 8317)
id Name Status NCT ID Phase
1 Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02097342 Phase 4
2 Chronic Treatment With Benfotiamine Restores Endothelial Function in People With Type 2 Diabetes Mellitus Unknown status NCT00446810 Phase 4
3 A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients Unknown status NCT00336310 Phase 4
4 Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus Unknown status NCT01206647 Phase 4
5 A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes Unknown status NCT00144144 Phase 4
6 Continuous Glucose Monitoring in Patients With Type 2 Diabetes Unknown status NCT00529815 Phase 4
7 Bone Turnover in Type 2 Diabetes Patients Unknown status NCT00732121 Phase 4
8 Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding Unknown status NCT01597531 Phase 4
9 Multifactorial Intervention in Type 2 Diabetes - Italy Unknown status NCT01240070 Phase 4
10 Comparison of the Efficacy and Safety Between Pioglitazone and Placebo Added to Combination Therapy in Type 2 Diabetes Unknown status NCT00991055 Phase 4
11 Variation in Sulphonylurea Response in Type 2 Diabetes Unknown status NCT00738088 Phase 4
12 Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes Unknown status NCT01435980 Phase 4
13 Prevalence of Macrovascular Disease in Type 2 Diabetes Mellitus Unknown status NCT00298844 Phase 4
14 Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Unknown status NCT01267448 Phase 4
15 Type 2 Diabetes Mellitus and Atherosclerosis Unknown status NCT01250340 Phase 4
16 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4
17 Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes Unknown status NCT01758471 Phase 4
18 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4
19 Insulin Effects on Metabolism and Cardiovascular Function in Type 2 Diabetes Unknown status NCT00747409 Phase 4
20 The Efficacy of Glucerna SR in Chinese Drug-naïve Subjects With Type 2 Diabetes Unknown status NCT02248714 Phase 4
21 Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes Unknown status NCT02372955 Phase 4
22 How Does the Diabetes Drug, Pioglitazone, Reduce Protein Loss in the Urine? Unknown status NCT00749047 Phase 4
23 Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients Unknown status NCT00399204 Phase 4
24 The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion Unknown status NCT02406443 Phase 4
25 Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes Unknown status NCT00925119 Phase 4
26 Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices Unknown status NCT02361489 Phase 4
27 Efficacy and Safety of Lobeglitazone Versus Sitagliptin Unknown status NCT02480465 Phase 4
28 Thyroid Study Type 2 Diabetes Mellitus (T2DM) Unknown status NCT01379170 Phase 4
29 Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus Unknown status NCT00540462 Phase 4
30 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4
31 German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET) Unknown status NCT01409330 Phase 4
32 Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy Unknown status NCT02129985 Phase 4
33 Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus Unknown status NCT01547104 Phase 4
34 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
35 Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes Unknown status NCT00736515 Phase 4
36 Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes Unknown status NCT01867502 Phase 4
37 Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin Unknown status NCT02426294 Phase 4
38 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4
39 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4
40 the Effect of Vitamin D on the Serum Thioredoxin, TBP-2, Thioredoxin Reductase, Gene Expression of TBP-2 in Patients With Type II Diabetes Unknown status NCT01876563 Phase 4
41 Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4
42 The Impact of Omega-3 Supplementation on Gene Expression in Type 2 Diabetics Unknown status NCT01478776 Phase 4
43 Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells Unknown status NCT00523393 Phase 4
44 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4
45 Aspirin and Enalapril in Microalbuminuric Type 2 Diabetes Mellitus Patients Unknown status NCT00427271 Phase 4
46 the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin Unknown status NCT02438397 Phase 4
47 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
48 Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes Unknown status NCT01978405 Phase 4
49 Nephropathy In Type 2 Diabetes and Cardio-renal Events Unknown status NCT00535925 Phase 4
50 Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics Unknown status NCT01095822 Phase 4

Search NIH Clinical Center for Diabetes Mellitus, Noninsulin-Dependent

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cochrane evidence based reviews: diabetes mellitus, type 2

Genetic Tests for Diabetes Mellitus, Noninsulin-Dependent

Genetic tests related to Diabetes Mellitus, Noninsulin-Dependent:

id Genetic test Affiliating Genes
1 Diabetes Mellitus Type 2 29
2 Insulin Resistance 29
3 Diabetes Mellitus, Noninsulin-Dependent 24 NEUROD1

Anatomical Context for Diabetes Mellitus, Noninsulin-Dependent

MalaCards organs/tissues related to Diabetes Mellitus, Noninsulin-Dependent:

39
Eye, Kidney, Pancreas, Testes, Heart, Bone, T Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Diabetes Mellitus, Noninsulin-Dependent:
id Tissue Anatomical CompartmentCell Relevance
1 Pancreas Islets of Langerhans Mature Beta Cells Potential therapeutic candidate, affected by disease
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Diabetes Mellitus, Noninsulin-Dependent